You are viewing: France Leukapheresis Market analysis
Part of: Leukapheresis Market (Global)

The France Leukapheresis Market was valued at $3.65 Million in 2026 and projected to reach to $5.17 Million by 2031, representing a compound annual growth rate of CAGR 7.2%. France's leukapheresis market is positioned for consistent growth driven by the country's advanced healthcare infrastructure and increasing prevalence of hematologic malignancies requiring cell therapy interventions.

France Leukapheresis Market (2026-2031) : Size and Share
logo-mobile
CAGR of
cagr-Chart
USD Million
MARKET SNAPSHOT
Market Size in USD 26.32 MN
Market Forecast in
CAGR
Forecast Period
Units Considered Value (USD MN)

France Leukapheresis Market Trends and Insights

  • This growth trajectory reflects France's advancing healthcare infrastructure and increasing adoption of cell therapy technologies within the country's medical centers.
  • France's market expansion is driven by rising demand for therapeutic apheresis procedures and growing investment in hematologic and oncologic treatment protocols across French hospitals and specialized clinics. The leukapheresis sector in France benefits from strong regulatory support and established reimbursement frameworks that facilitate patient access to advanced cell collection technologies.
  • France's commitment to precision medicine and cellular immunotherapy has positioned the country as a key market within Europe for leukapheresis equipment and services.
  • Between 2026 and 2031, France is expected to see increased deployment of automated apheresis systems and enhanced clinical protocols, supporting the market's steady upward trajectory..

Key Market Statistics

  • CAGR (2026-2031) CAGR 7.2%
  • Market Size, 2026 ~USD 3.65 Million
  • Forecast, 2031 ~USD 5.17 Million
  • Country France

France Leukapheresis Market Overview

Market Size & Growth :

France's leukapheresis market is valued at USD 3.65 million in 2026 and is projected to reach USD 5.17 million by 2031, with a steady CAGR of 7.2%, outpacing many European counterparts.

Healthcare Infrastructure Advancement :

France's robust healthcare system and investment in advanced medical technologies are driving adoption of leukapheresis procedures across major medical centers and specialized treatment facilities.

Cell Therapy Expansion :

Increasing clinical applications of CAR-T cell therapies and other cell-based treatments in France are creating sustained demand for leukapheresis equipment and services in oncology and hematology departments.

Regulatory Support & Innovation :

France's favorable regulatory environment and participation in European clinical trials are accelerating the adoption of leukapheresis technologies and supporting market growth through institutional partnerships.

France Leukapheresis Market Dynamics

  • The market benefits from strong institutional support, with major French medical centers investing in state-of-the-art apheresis equipment and trained personnel to meet growing clinical demand. Looking ahead to 2031, France's market expansion will be supported by rising awareness of personalized medicine, expanding CAR-T cell therapy programs, and increased reimbursement coverage for leukapheresis procedures.
  • Strategic partnerships between French healthcare providers and international cell therapy manufacturers are expected to further accelerate market penetration and drive innovation in treatment protocols..

Related Ecosystem

Key Takeaways

  • France's leukapheresis market is valued at USD 3.65 million in 2026 and will reach USD 5.17 million by 2031.
  • France demonstrates a 7.2% CAGR, reflecting steady growth in cell therapy adoption and therapeutic apheresis demand.
  • France's robust healthcare infrastructure and reimbursement policies support market expansion and technology deployment.
  • France is positioned as a key European hub for leukapheresis innovation and cellular immunotherapy advancement.

Leukapheresis Market Report Scope

Report Metric Details
Base Year 2026
Fastest Growing Segment MULTIPLE MYELOMA (Indication)
Forecast Period 2026–2031
Growth Rate CAGR of 8.9% from 2026 to 2031
Largest Segment ACUTE LYMPHOCYTIC LEUKEMIA (Indication)
Market Size Base Year (Billions) ~USD 0.09 (2026)
Revenue Forecast (Billions) ~USD 0.14 (2031)
Segments Covered Product Type, Product Type 2024–2031, Type, Application, End User, Indication, Leukopak Type

France Leukapheresis Market Report Segmentation

7 segment dimensions are covered across the global market.

By Product Type

  • Devices
  • Disposables
  • Leukapheresis Devices
  • Leukapheresis Disposables

By Product Type 2024–2031

  • Collection Kits & Accessories
  • Filters & Membrane Consumables
  • Tubing Sets & Collection Bag

By Type

  • Australia
  • Belgium
  • Brazil
  • Canada
  • Centrifugal Devices
  • China
  • Diseased Leukopaks
  • France
  • Germany
  • India
  • Isolated Pbmcs
  • Italy
  • Japan
  • Kingdom Of Saudi Arabia (Ksa)
  • Membrane Separators
  • Mexico
  • Mobilized Leukopaks
  • Netherlands
  • New Zealand
  • Non-Mobilized Leukopaks
  • Poland
  • Rest Of Asia Pacific
  • Rest Of Europe
  • Rest Of GCC Countries
  • Rest Of Latin America
  • Rest Of Middle East & Africa
  • South Korea
  • Spain
  • Switzerland
  • Thailand
  • UK
  • United Arab Emirates (UAE)
  • US

By Application

  • Research Applications
  • Therapeutic Applications

By End User

  • Academic & Research Institutes
  • Blood Component Providers & Blood Centers
  • Contract Research Organizations
  • Hospitals & Transfusion Centers
  • Pharmaceutical & Biotechnology Companies

By Indication

  • Acute Lymphocytic Leukemia
  • Chronic Lymphocytic Leukemia
  • Hepatocellular Carcinoma
  • Multiple Myeloma
  • Non-Hodgkin’S Lymphoma
  • Other Indications
  • Pancreatic Cancer

By Leukopak Type

  • Diseased Leukopaks
  • Isolated Pbmcs
  • Mobilized Leukopaks
  • Non-Mobilized Leukopaks

Target Audience

  • Medical Device Manufacturers : Leukapheresis equipment and apheresis system providers need France-specific market data to assess market opportunity, identify key hospital accounts, and develop localized sales strategies.
  • Cell Therapy Companies : CAR-T and cell therapy developers require insights into France's treatment adoption rates, clinical infrastructure, and reimbursement landscape to support commercial expansion and clinical program planning.
  • Healthcare Investors & PE Firms : Investment professionals evaluating opportunities in French healthcare technology need market sizing, growth projections, and competitive analysis to support investment thesis development and valuation modeling.
  • Hospital & Medical Center Administrators : French healthcare facility leaders need market intelligence on leukapheresis demand trends, technology adoption benchmarks, and budget forecasting to support capital equipment planning and service expansion.
  • Market Research & Consulting Firms : Research organizations and consultants serving healthcare clients require verified France market data and forecasts to support client advisory projects, competitive analysis, and strategic planning engagements.

Key Companies in the France Leukapheresis Market

CompanyHQOwnershipStrongest segments
MAXCYTE, INCUnited StatesPublic CompanyExPERT instruments (ATx, STx, GTx, VLx),Disposable processing assemblies (PAs) and consumables,Licensing and technology access fees,

MAXCYTE, INC

MaxCyte, Inc. is a United States-based biotechnology company founded in 1998 that specializes in cell engineering technologies. As a publicly traded company, MaxCyte operates with 91 employees and develops innovative solutions for cell-based therapies and research applications.

Reasons to Buy this Report

  • Country-Specific Market Sizing : Obtain precise market valuation for France with verified 2026 baseline (USD 3.65M) and 2031 forecast (USD 5.17M), enabling accurate budget allocation and revenue projections for French market entry or expansion.
  • Competitive Landscape Intelligence : Understand France-specific competitive dynamics, key players operating in French medical centers, and market share distribution to identify partnership opportunities and differentiation strategies.
  • Regulatory & Reimbursement Insights : Access detailed analysis of French healthcare regulations, reimbursement policies, and institutional procurement processes specific to leukapheresis services and equipment.
  • Growth Driver Analysis : Identify France-specific growth catalysts including cell therapy adoption rates, clinical trial activity, and healthcare infrastructure investments driving the 7.2% CAGR through 2031.
  • Strategic Market Entry Planning : Develop informed go-to-market strategies for France with localized insights on hospital networks, key opinion leaders, and institutional decision-making processes in French healthcare.

Frequently asked questions

What is the current size of the leukapheresis market in France?

The leukapheresis market in France is estimated at USD 3.65 million in 2026.

What is the projected market size for leukapheresis in France by 2031?

France's leukapheresis market is projected to reach USD 5.17 million by 2031.

What is the growth rate of the leukapheresis market in France?

France's leukapheresis market is growing at a CAGR of 7.2% from 2026 to 2031.

What factors are driving growth in France's leukapheresis market?

Growth in France is driven by increasing adoption of cell therapy technologies, rising demand for therapeutic apheresis, and strong regulatory and reimbursement support for advanced medical procedures.

How does France's leukapheresis market compare to other European markets?

France represents a significant European market for leukapheresis with established healthcare infrastructure, regulatory frameworks, and commitment to precision medicine that support steady market expansion.

RESEARCH METHODOLOGY

This study extensively used both primary and secondary sources. The research involved studying various factors affecting the industry to identify segmentation types, industry trends, key players, competitive landscape, key market dynamics, and key player strategies.

Secondary Research

This research study involved the usage of comprehensive secondary sources, directories, databases such as Bloomberg Business, Factiva, and Dun & Bradstreet; white papers; annual reports; company house documents; investor presentations; and SEC filings of companies. Secondary research was used to identify and collect information useful for an extensive, technical, market-oriented, and commercial study of the leukapheresis market. It was also used to identify key players in the market and classify and segment the industry based on trends to the most detailed level. Additionally, significant developments related to market and technology perspectives were noted. A database of the primary industry leaders was also created using secondary research.

Primary Research

In the primary research process, various sources from both the supply and demand sides were interviewed to obtain qualitative and quantitative information for this report. Primary sources from the supply side include project/sales/marketing/business development managers, presidents, CEOs, vice presidents, chairpersons, chief operating officers, chief strategy officers, directors, chief information officers, and chief medical information officers related to the leukapheresis market. Primary sources from the demand side include healthcare professionals from blood component providers & blood centers, academic & research institutes, pharmaceutical & biotechnology companies, and hospitals & transfusion centers.

A breakdown of the primary respondents is provided below:

BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE PARTICIPANTS, BY COMPANY TYPE, DESIGNATION, AND REGION

Leukapheresis Market
Size, and Share

Note 1: C-level executives include CEOs, COOs, CTOs, and VPs.
Note 2: Other designations include sales, marketing, and product managers.

Note 3: Tiers are defined based on a company’s total revenue. As of 2024: Tier 1 = >USD 1 billion, Tier 2 = USD 500 million to USD 1 billion, and Tier 3 = <USD 500 million

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

The total size of the leukapheresis market was determined after data triangulation from three approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Leukapheresis Market Top Down and Bottom Up Approach

Data Triangulation

After arriving at the market size, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were employed wherever applicable to complete the overall market engineering process and arrive at the exact statistics for all segments and subsegments.

Market Definition

Leukapheresis is the process of separating white blood cells from the whole blood. Therapeutic leukapheresis procedures are used to treat hyperleukocytic leukemia, including acute lymphoblastic leukemia (ALL), chronic lymphocytic leukemia (CLL), multiple myeloma, and non-Hodgkin’s lymphoma.

Leukopaks are enriched leukapheresis products that contain mononuclear leukocytes (lymphocytes and monocytes) and are used to develop cell-based therapeutics

Key Stakeholders

  • Apheresis device manufacturers and distributors
  • Leukapheresis product manufacturers and distributors
  • Leukopak manufacturers and distributors
  • Pharmaceutical and biotechnology companies
  • Healthcare service providers (including hospitals and transfusion centers)
  • Cancer treatment centers
  • Blood component providers & blood centers
  • Contract research organizations (CROS)
  • Academic and research institutes
  • Government associations
  • Market research and consulting firms
  • Venture capitalists and investors

Report Objectives

  • To define, describe, segment, and forecast the leukapheresis market by type, application, end user, and region, and the leukopaks market, by type, indication, end user, and region
  • To provide detailed information about the factors influencing market growth (such as drivers, restraints, opportunities, and challenges)
  • To analyze micromarkets with respect to individual growth trends, prospects, and contributions to the overall leukapheresis market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key players
  • To forecast the size of the leukapheresis market in five main regions (along with their respective key countries), namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa
  • To profile the key players in the leukapheresis market and comprehensively analyze their core competencies and market share
  • To track and analyze competitive developments such as acquisitions, product launches, expansions, collaborations, agreements, and partnerships

Available customizations:

With the given market data, MarketsandMarkets offers customizations to meet your company’s specific needs. The following customization options are available for the report:
  • Company Information

Detailed analysis and profiling of additional market players (up to 5)

  • Geographic Analysis

Further breakdown of the Rest of Europe leukapheresis market into Austria, Finland, and other countries

Further breakdown of the Rest of Latin America leukapheresis market into Colombia, Chile, and other countries

  • Competitive Landscape Assessment

Market share analysis for North America and Europe, which provides market shares of the top 3–5 key players in the leukapheresis market

Competitive leadership mapping for established players in the US

 

Get the Full Leukapheresis Market Report

Full forecast, segment splits, and company analysis for all Leukapheresis Market.

Need a Tailored Report?

Customize this report to your needs

Get 10% FREE Customization

Customize This Report
Fact checked
DMCA.com Protection Status